The NMD escape mechanism and its application in disease therapy
Received date: 2019-12-20
Revised date: 2020-02-25
Online published: 2020-03-06
Supported by
Supported by Beijing Natural Science Foundation(No.5163028);the National Natural Science Foundation of China No(81500979);CAMS Initiative for Innovative Medicine No(2016YFC0901505);CAMS Initiative for Innovative Medicine No(2016-I2M-1-008)
Nonsense-mediated mRNA decay (NMD) refers to the degradation of mRNA due to the presence of premature stop codon (PTC) on mRNA under pathological or physiological conditions. NMD is widely considered an mRNA-specific quality control process. Recently it was discovered that some PTCs do not trigger NMD in a variety of diseases - a process known as NMD escape; however, its exact mechanism remains unclear. At present, there are two widely accepted mechanistic hypotheses during NMD escape. The first is PTC read-through, in which protein translation undergoes PTC until the normal stop codon is encountered, producing a full-length protein. The second is translation reinitiation, in which protein translation recommences at the potential start codon downstream of PTC and terminates at the stop codon, producing an N-terminal truncated protein. Currently, an increasing number of drugs or small molecules that use PTC read-through have been successfully applied to treat nonsense variation-associated diseases. In this review, we summarize the NMD mechanism and discuss the application and progress in our understanding of NMD escape in disease therapy. This review should provide a useful framework to advance current understanding of the research and application of NMD escape.
Miaomiao Cheng, Yanyan Cao . The NMD escape mechanism and its application in disease therapy[J]. Hereditas(Beijing), 2020 , 42(4) : 354 -362 . DOI: 10.16288/j.yczz.19-335
| [1] | Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N, Mühlemann O . Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci, 2010,67(5):677-700. |
| [2] | Schoenberg DR, Maquat LE . Regulation of cytoplasmic mRNA decay. Nat Rev Genet, 2012,13(4):246-259. |
| [3] | Celik A, Kervestin S, Jacobson A . NMD: At the crossroads between translation termination and ribosome recycling. Biochimie, 2015,114:2-9. |
| [4] | Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE . NMD: RNA biology meets human genetic medicine. Biochem J, 2010,430(3):365-377. |
| [5] | GUO WT, XU WY, GU MM . Nonsense-mediated mRNA decay and human monogenic disease. Hereditas(Beijing), 2012,34(8):935-942. |
| [5] | 郭文婷, 徐汪洋, 顾鸣敏 . 无义介导的mRNA降解机制及其在单基因遗传病中的作用. 遗传, 2012,34(8):935-942. |
| [6] | Nagy E, Maquat LE . A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem Sci, 1998,23(6):198-199. |
| [7] | Jagannathan S, Bradley RK . Translational plasticity facilitates the accumulation of nonsense genetic variants in the human population. Genome Res, 2016,26(12):1639-1650. |
| [8] | Neu-Yilik G, Amthor B, Gehring NH, Bahri S, Paidassi H, Hentze MW, Kulozik AE . Mechanism of escape from nonsense-mediated mRNA decay of human β-globin transcripts with nonsense mutations in the first exon. RNA, 2011,17(5):843-854. |
| [9] | Peixeiro I, Inácio ?, Barbosa C, Silva AL, Liebhaber SA, Rom?o L . Interaction of PABPC1 with the translation initiation complex is critical to the NMD resistance of AUG-proximal nonsense mutations. Nucleic Acids Res, 2012,40(3):1160-1173. |
| [10] | Pereira FJ, Teixeira A, Kong J, Barbosa C, Silva AL, Marques-Ramos A, Liebhaber SA, Rom?o L . Resistance of mRNAs with AUG-proximal nonsense mutations to nonsense-mediated decay reflects variables of mRNA structure and translational activity. Nucleic Acids Res, 2015,43(13):6528-6544. |
| [11] | Keeling KM, Bedwell DM . Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA, 2011,2(6):837-852. |
| [12] | Dunkle JA, Dunham CM . Mechanisms of mRNA frame maintenance and its subversion during translation of the genetic code. Biochimie, 2015,114:90-96. |
| [13] | Bidou L, Allamand V, Rousset JP, Namy O . Sense from nonsense: therapies for premature stop codon diseases. Trend Mol Med, 2012,18(11):679-688. |
| [14] | Fu Y, Shu ZY, Gu MM , The functional mechanisms and clinical application of Read-through drugs. Hereditas (Beijing), 2016,38(7):623-633. |
| [14] | 付洋, 舒在悦, 顾鸣敏 . 促通读药物的作用机制与临床应用. 遗传, 2016,38(7):623-633. |
| [15] | Kaler SG, Tang JR, Donsante A, Kaneski CR . Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann Neurol, 2009,65(1):108-113. |
| [16] | Guni?ová S, Hronová V, Mohammad MP, Hinnebusch AG, Valá?ek LS . Please do not recycle! Translation reinitiation in microbes and higher eukaryotes. FEMS Microbiol Rev, 2018,42(2):165-192. |
| [17] | Hulsebos TJ, Kenter S, Verhagen WI, Baas F, Flucke U, Wesseling P . Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis- associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathol, 2014,128(3):439-448. |
| [18] | Stump MR, Gong QM, Zhou ZF . LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation. Am J Physiol Heart Circ Physiol, 2013,305(9):H1397-H1404. |
| [19] | Hronová V, Mohammad MP, Wagner S, Pánek J, Guni?ová S, Zeman J, Poncová K, Valá?ek LS . Does eIF3 promote reinitiation after translation of short upstream ORFs also in mammalian cells? RNA Biology, 2017,14(12):1660-1667. |
| [20] | Mohammad MP, Munzarová Pondělí?kováV, Zeman J, Guni?ová S, Valá?ek, LS . In vivo evidence that eIF3 stays bound to ribosomes elongating and terminating on short upstream ORFs to promote reinitiation. Nucl Aci Res, 2017,45(5):2658-2674. |
| [21] | Billack B, Monteiro AN . BRCA1 in breast and ovarian cancer predisposition. Cancer Lett, 2005,227(1):1-7. |
| [22] | Buisson M, Anczuków O, Zetoune AB, Ware MD, Mazoyer S . The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Human Mutation, 2006,27(10):1024-1029. |
| [23] | Krempely K, Karam R . A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense- mediated mRNA decay. Cold Spring Harb Mol Case Stu, 2018,4(4):a003012. |
| [24] | Loughran G, Jungreis I, Tzani I, Power M, Dmitriev RI, Ivanov IP, Kellis M, Atkins JF . Stop codon readthrough generates a C-terminally extended variant of the human vitamin D receptor with reduced calcitriol response. J Biol Chem, 2018,293(12):4434-4444. |
| [25] | Toma KG, Rebbapragada I, Durand S, Lykke-Andersen J . Identification of elements in human long 3' UTRs that inhibit nonsense-mediated decay. RNA, 2015,21(5):887-897. |
| [26] | Keeling KM, Wang D, Conard SE, Bedwell DM. Suppression of premature termination codons as a therapeutic approach. Critic Rev Biochem Mol Biol, 2012,47(5):444-463. |
| [27] | Matalonga L, Arias á, Tort F, Ferrer-Cortés X, Garcia-Villoria J, Coll MJ, Gort L, Ribes A . Effect of readthrough treatment in fibroblasts of patients affected by lysosomal diseases caused by premature termination codons. Neurotherapeutics, 2015,12(4):874-886. |
| [28] | Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet, 2009,18(7):1310-1322. |
| [29] | Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL . Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet, 2006,120(4):589-601. |
| [30] | Moosajee M, Gregory-Evans K, Ellis CD, Seabra MC, Gregory-Evans CY . Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet, 2008,17(24):3987-4000. |
| [31] | Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, Bedwell DM, Keeling KM . The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab, 2012,105(1):116-125. |
| [32] | Nagel-Wolfrum K, Moller F, Penner I, Wolfrum U . Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations. Vis Neurosci, 2014,31(4-5):309-316. |
| [33] | Scheunemann AE, Graham WD, Vendeix FA, Agris PF . Binding of aminoglycoside antibiotics to helix 69 of 23S rRNA. Nucleic Acids Res, 2010,38(9):3094-3105. |
| [34] | Eustice DC, Wilhelm JM . Fidelity of the eukaryotic codon-anticodon interaction: interference by aminoglycoside antibiotics. Biochemistry, 1984,23(7):1462-1467. |
| [35] | Lee HL, Dougherty JP . Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther, 2012,136(2):227-266. |
| [36] | Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, Schwinger E, Hopwood JJ, Scott HS, Gal A . Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common α-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Gen, 1994,3(6):861-866. |
| [37] | Keeling KM, Brooks DA, Hopwood JJ, Li PN, Thompson JN, Bedwell DM . Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Gen, 2001,10(3):291-299. |
| [38] | Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen GM, Jones S, Ren HY, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng HS, Jacobson A, Peltz SW, Sweeney HL . PTC124 targets genetic disorders caused by nonsense mutations. Nature, 2007,447:87-91. |
| [39] | Finkel RS . Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol, 2010,25(9):1158-1164. |
| [40] | Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D . Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet, 2004,41(7):508-517. |
| [41] | Bordeira-Carri?o R, Ferreira D, Mateus DD, Pinheiro H, Pêgo AP, Santos MA, Oliveira C . Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. Eur J Hum Genet, 2014,22(9):1085-1092. |
| [42] | Ma ZP, Chen J . Nonsense mutations and genetic compensation response. Hereditas(Beijing), 2019,41(5):359-364. |
| [42] | 马志鹏, 陈军 . 无义突变与“遗传补偿效应”. 遗传, 2019,41(5):359-364. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
